Serial hybrid atrial fibrillation ablation - SHAFT

Medisch Spectrum Twente0 个研究点目标入组 80 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•All patients screened are accepted for pulmonary vein isolation according to the current guidelines.
•1) candidates for enrolment should have long standing persistent or persistent AF as defined in the guidelines for which they received at least one cardioversion with EHRA class * II
•2) Furthermore, on echocardiogram left atrial size needs to be more than >46 mm on long axis or >35 cc/m2.

•1) Significant coronary artery disease has to be excluded as a trigger for AF by means of cardiac CT, if necessary a coronary angiogram will be performed.
•2) Previous pulmonary vein isolation (epicardial or endocardial) or cardiac surgery. 3) Significant valvular disease present on echo (mitral or aortic valve regurgitation above grade 2, moderate to severe mitral or aortic stenosis). 4) Concomitant cardiac surgery needed 5) left ventricular ejection fraction <40% 6) hypertrophic (obstructive) cardiomyopathy or dilated cardiomyopathy defined as an ejection fraction < 40% 7) active infection or sepsis 8) pregnancy 9) myocardial infarction within the previous 3 months 10) AF secondary to electrolyte imbalance, thyroid disease, other reversible or noncardiovascular causes for AF 11) known sensitivity to heparin or warfarin 12) life expectancy of <12 months 13) pleural adhesions 14) prior thoracotomy 15) patients on dialysis

发起方